Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2640 Safety and PK/PD in Healthy Subjects and T1DM
NCT02269735Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2014
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, double-blind trial of MK-2640 in type 1 diabetes mellitus (T1D), sponsored by Merck & Co. Started Nov 2014; status: completed.
02
Drugs
MK-2640
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02269735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269735.